All In Biotech

BLA 761033 · Teva Respiratory LLC

Cinqair

Reslizumab · Injection · Interleukin-5 Antagonist

Novel

Last checked: Nov 20, 2026Latest source record: Jan 9, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Mar 23, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

23

13 Phase 3, 2 recruiting

FAERS reports

688

443 serious, 17 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: ANAPHYLAXIS Anaphylaxis has been observed with CINQAIR infusion in 0.3% of patients in placebo-controlled clinical studies. Anaphylaxis was reported as early as the second dose of CINQAIR [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6 )] . Anaphylaxis can be life-threatening. Patients should be observed for an appropriate period of time after CINQAIR administration by a healthcare professional prepared to manage anaphylaxis. Discontinue CINQAIR immediately if the patient experiences signs or symptoms of anaphylaxis [see Dosage and Administration ( 2.2 ), Warnings and Precautions ( 5.1 )] . WARNING: ANAPHYLAXIS See full prescribing information for complete boxed warning. Anaphylaxis occurred with CINQAIR infusion in 0.3% of patients in placebo-controlled studies ( 5.1 ) Patients should be observed for an appropriate period of time after CINQAIR infusion; healthcare...

What it is approved for

From the label in effect Feb 29, 2020.

CINQAIR ® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies ( 14 )] . Limitation of Use: CINQAIR is not indicated for treatment of other eosinophilic conditions. CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . CINQAIR is an interleukin-5 antagonist monoclonal antibody (IgG4 kappa) indicated for add-on maintenance treatment of patients with severe asthma aged 18 years and older, and with an eosinophilic phenotype ( 1 ). Limitations of Use : CINQAIR is not indicated for: treatment of other eosinophilic conditions ( 1 ) relief of acute bronchospasm or status asthmaticus ( 1 )

Mechanism: Reslizumab is an interleukin-5 antagonist (IgG4, kappa). IL-5 is the major cytokine responsible for the growth and differentiation, recruitment, activation, and survival of eosinophils. Reslizumab binds to IL-5 with a dissociation constant of 81 pM, inhibiting the bioactivity of IL-5 by blocking its binding to the alpha chain of the IL-5 receptor complex expressed on the eosinophil surface. Inflammation is an important component in the pathogenesis of asthma. Multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids,...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • CINQAIR · RESLIZUMAB 100MG/10ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Reslizumab" as an intervention, any sponsor and status, largest first.

All 23 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea96
  • asthma95
  • incorrect dose administered88
  • drug ineffective83
  • hypertension73
  • cough47
  • headache43
  • wheezing40
  • fatigue39
  • pneumonia33
  • inappropriate schedule of product administration32
  • oropharyngeal pain31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20141
201619
201790
201893
201958
202066
202172
202276
202345
202455
202573
202639

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cinqair (Reslizumab)

2024 spending

$962K

Beneficiaries

26

237 claims

Per beneficiary

$37,010

$106.44 per unit

View as table
YearSpending
2020$889,073
2021$1,039,210
2022$860,241
2023$955,768
2024$962,250

Part B: Cinqair (Reslizumab) · HCPCS J2786

2024 spending

$8.6M

Beneficiaries

302

2,890 claims

Per beneficiary

$28,477

2024 ASP limit $10.20 per unit

View as table
YearSpending
2020$11,663,482
2021$11,402,565
2022$11,088,289
2023$9,788,941
2024$8,600,043

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 69 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.